0001209191-21-054168.txt : 20210831 0001209191-21-054168.hdr.sgml : 20210831 20210831194932 ACCESSION NUMBER: 0001209191-21-054168 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210830 FILED AS OF DATE: 20210831 DATE AS OF CHANGE: 20210831 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ORDAN MARK S CENTRAL INDEX KEY: 0001208541 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12111 FILM NUMBER: 211228398 MAIL ADDRESS: STREET 1: 7315 WISCONSIN AVENUE STREET 2: SUITE #250 WEST CITY: BETHESDA STATE: MD ZIP: 20814 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MEDNAX, INC. CENTRAL INDEX KEY: 0000893949 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 263667538 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 BUSINESS PHONE: 9543840175 MAIL ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 FORMER COMPANY: FORMER CONFORMED NAME: PEDIATRIX MEDICAL GROUP INC DATE OF NAME CHANGE: 19950801 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-30 0 0000893949 MEDNAX, INC. MD 0001208541 ORDAN MARK S 1301 CONCORD TERRACE SUNRISE FL 33323 1 1 0 0 Chief Executive Officer Common Stock 2021-08-30 4 M 0 95000 17.65 A 303425 D Common Stock 2021-08-30 4 S 0 95000 35.09 D 208425 D Employee Stock Option (right to buy) 17.65 2021-08-30 4 M 0 95000 17.65 D 2023-10-10 Common Stock 95000 455331 D Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"). The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date. /s/ Dominic J. Andreano, as Attorney-in-Fact 2021-08-31